Navigate Fool.com
Will AMRN beat
the market?

Amarin Corp plc (ADR)


Community Rating: 3 Stars: Appealing

1.58 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.60
Previous Close $1.58
Daily Range $1.55 - $1.65
52-Week Range $1.36 - $7.98
Market Cap $272.5M
P/E Ratio -1.25
Dividend (Yield) $0.00 (0.0%)
Volume 937,324
Average Daily Volume 2,490,204
Current FY EPS -$0.63

How do you think AMRN
will perform against the market?

Top AMRN Bull/Bear Pitches


zzlangerhans (< 20)
Submitted June 11, 2011

Amarin had their own little flash crash today after some remarks by the CEO that indicated he wasn't dying to unload the company immediately. It was the latest in a series of statements that have shak … More

2 Replies Reply Report this Post

zzlangerhans (< 20)
Submitted March 25, 2010

Hemispheryx has Ampligen and Amarin has ethyl-EPA. Neither of these companies will let repeated trial failures prevent them from flogging their single pipeline products in new studies for new indicati … More

1 Replies Reply Report this Post

News & Commentary

The Supreme Court Will Decide the Fate of a Blockbuster

Teva's day in court is coming.

More Trouble Looming for Amarin Corporation?

Teva announced yesterday that it's launching a generic version of GlaxoSmithKline's Lovaza. Will this launch hurt Amarin's competing product?

Partner Signed! Is Amarin's Turnaround Beginning?

Amarin Corporation plc (ADR) signed Japan's Kowa Pharmaceuticals as a marketing partner for Vascepa.

Can This Drive Growth for Amarin Corporation plc?

A co-promotion agreement with Kowa seems like a reasonable way to drive badly-needed sales growth

Sector Update: Healthcare Shares Flat in Pre-Market Trade; Amarin Partners with Kowa to Promote Vasc

Sector Update: Healthcare Shares Flat in Pre-Market Trade; Amarin Partners with Kowa to Promote Vascepa

Sector Update: Healthcares

Better Chance of Making a Comeback: Amarin plc or VIVUS, Inc.?

Amarin and VIVUS have both fallen on hard times. Which stock has the best chance to regain its former glory?

Are Biotech Stocks Located in Ireland Top Buyout Candidates?

If You Can't Make Your Drug a Blockbuster, Sue Your Competitor

Amarin sues AstraZeneca over its fish oil pill Epanova. If the companies can't reach sales close to GlaxoSmithKline's Lovaza, it will be for naught.

What This FDA Decision Means for Amarin Investors

Investors barely twitched when Amarin Corp. (NASDAQ: AMRN) announced earlier that the FDA had denied new chemical entity status for Vascepa, its fish oil-based therapy for high triglycerides—and for good reason. Amarin's stock hit bottom hard in October when the EMDAC vote went against the drug, and the biotech's flatlined stock is unlikely to do anything interesting until the outcome of its legal wrangling with the FDA is determined.

See More AMRN News...





Amarin Corp plc (ADR) (AMRN) Description

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders. Website: http://www.amarincorp.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks